Overview
Severe acute respiratory syndrome (SARS) is a viral respiratory illness that can be fatal and contagious. Both SARS and COVID-19 are caused by SARS-associated coronaviruses. SARS is caused by the virus SARS-CoV and COVID-19 is caused by the virus SARS-CoV2. Infections like SARS-CoV and COVID-19 occur in both animals and humans.
According to the Center for Disease Control and Prevention (CDC) and the World Health Organization (WHO), the first case of SARS was detected in South China in November 2002 and later in March 2003. SARS was then identified as a global hazard. As stated by the Center for Disease Control and Prevention (CDC), from November 2002 to July 2003, a total of 8,098 people became sick with severe acute respiratory syndrome in the world and 774 of them died. No new cases of SARS-CoV after July 2003 have been reported yet. The treatment of SARS-CoV is still evolving and no optimal cure has been found so far.
However, the recent outbreak of COVID-19 disease created havoc in the world and is still affecting millions of people worldwide. As mentioned by the World Health Organization, it was first reported in Wuhan, China on December 31, 2019 and further declared as a global pandemic by the World Health Organization in March 2020.
The healthcare system is under strain as a result of the alarming number of cases and deaths due to COVID-19. Scientists and research institutes worldwide are racing against the clock to find a cure for COVID-19.
Get Free Sample PDF Copy (Including Full TOC, List of Tables & Figures, Chart) @
https://www.coherentmarketinsights.com/insight/request-sample/4494
Market Drivers:
Rising cases of COVID-19 are expected to propel growth of the global severe acute respiratory syndrome (SARS) treatment market across the globe over the forecast period. As stated by the World Health Organization, over 170.8 million confirmed cases and 3.5 million deaths of coronavirus disease (COVID-19) were reported up to June 2, 2021 across the globe.
Increasing drug approvals for emergency use authorization (by regulatory authorities) for the treatment of COVID-19 has led to a dynamic surge in the global severe acute respiratory syndrome (SARS) treatment market. the Drug Controller General of India approved the drug known as 2-DG, which is a powdered form of the molecule 2-deoxy-D-glucose developed by the Institute of Nuclear Medicine and Allied Sciences (INMA), a leading laboratory of the Defense Research and Development Organization (DRDO) in collaboration with Dr. Reddy’s laboratories (DRL), for emergency use in May 2021. The results of the clinical trials demonstrated that 2-DG helps moderate and severe COVID-19 patients recover faster and also decrease the need for supplemental oxygen. Moreover, the US Food and Drug Administration (FDA) approved GlaxoSmithKline’s developed medication known as Sotrovimab for emergency use on June 1, 2021. Sotrovimab is a monoclonal antibody that would be used for treating mild-to-moderate COVID-19 patients.
In addition, scientists are still researching and experimenting for a valid cure for COVID-19, which leaves scope for more new launches in the future, thereby leading to a boost in the global severe acute respiratory syndrome (SARS) treatment market. According to the U.S. Food and Drug Administration (FDA) Coronavirus Treatment Acceleration Program (CTAP) dashboard, as of April 2021, more than 610 drug development programs are in planning stages and more than 450 trials are being reviewed for the treatment of COVID-19.
Regional Insights:
Due to the high number of drug approvals for the treatment of COVID-19 in hospitals, North America was found to dominate the global severe acute respiratory syndrome (SARS) treatment market growth. The FDA approved Remdesivir in November 2020, manufactured by Gilead Sciences, a biopharmaceutical company focused on manufacturing antiviral drugs, as the first treatment against COVID-19 disease.
Asia Pacific is expected to show lucrative growth during the forecast period, owing to increased production of drugs for COVID-19 treatment by market players in order to combat the pandemic. In May 2020, almost 70 metric tons of hydroxychloroquine were manufactured in India by Zydus Cadila and Ipca laboratories, and exported to neighboring countries along with the U.S. Zydus Cadila and Ipca Labs are international pharmaceutical companies that manufacture generic drugs and active pharmaceutical ingredients, respectively.
Request PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/4494
Competitive Landscape
Major companies contributing to the global severe acute respiratory syndrome (SARS) treatment market include Pfizer Inc., Novartis, Ipca laboratories, Cadila healthcare Ltd., Cipla Ltd., Boehringer Ingelheim, Gilead Sciences Inc., AstraZeneca, Hetero labs Ltd., Eli Lily & Co., Johnson & Johnson, Takeda Ltd., GlaxoSmithKline, AbbVie, and Roche Holding AG.
Reasons to buy this Severe Acute Respiratory Syndrome (SARS) Treatment Market Report
◘ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Severe Acute Respiratory Syndrome (SARS) Treatment Market
◘ Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Severe Acute Respiratory Syndrome (SARS) Treatment Market
◘ Leading company profiles reveal details of key Severe Acute Respiratory Syndrome (SARS) Treatment Market players emerging five operations and financial performance
◘ Add weight to presentations and pitches by understanding the future growth prospects of the emerging Severe Acute Respiratory Syndrome (SARS) Treatment Market with five year historical forecasts
◘ Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Severe Acute Respiratory Syndrome (SARS) Treatment Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Severe Acute Respiratory Syndrome (SARS) Treatment Market are also given.
𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐟𝐟 @
https://www.coherentmarketinsights.com/promo/buynow/4494
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Severe Acute Respiratory Syndrome (SARS) Treatment Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Severe Acute Respiratory Syndrome (SARS) Treatment Industry Impact
Chapter 2 Global Severe Acute Respiratory Syndrome (SARS) Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Severe Acute Respiratory Syndrome (SARS) Treatment (Volume and Value) by Type
2.3 Global Severe Acute Respiratory Syndrome (SARS) Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Severe Acute Respiratory Syndrome (SARS) Treatment Sales, Consumption, Export, Import by Regions
Chapter 5 North America Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 6 East Asia Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 7 Europe Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 8 South Asia Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 9 Southeast Asia Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 10 Middle East Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 11 Africa Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 12 Oceania Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 13 South America Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Severe Acute Respiratory Syndrome (SARS) Treatment Business
Chapter 15 Global Severe Acute Respiratory Syndrome (SARS) Treatment Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology….
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837